Home Molecular Testing Methods Structural Variant Genetic Test: Inversions, Translocations, and Results

Structural Variant Genetic Test: Inversions, Translocations, and Results

By
Vita Library
-
4
Structural variant tests detect inversions, translocations, and complex chromosome changes. Learn which methods find balanced and unbalanced events and what results mean.

Structural variant genetic testing looks for large rearrangements in DNA, including inversions, translocations, insertions, deletions, duplications, and complex combinations of these events. Unlike a small sequence variant that changes one or a few bases, a structural variant changes the organization, orientation, location, or copy number of a larger DNA segment. It can disrupt a gene, separate it from its regulatory controls, create a fusion gene, or alter the amount of genetic material.

No single test detects every structural variant equally well. A karyotype can show large chromosome rearrangements but may miss small or cryptic breakpoints. Chromosomal microarray detects gains and losses but usually cannot identify balanced inversions or translocations. Genome sequencing and optical genome mapping can define more events at higher resolution, yet each has technical limits. The correct method depends on whether the concern is a constitutional disorder, infertility, recurrent pregnancy loss, prenatal finding, or cancer.

  • Structural variants rearrange larger segments of the genome rather than changing only one base.
  • Inversions reverse a segment; translocations move or exchange material between chromosome locations.
  • Balanced rearrangements may preserve total DNA amount but still disrupt genes or affect reproduction.
  • Unbalanced rearrangements create missing or extra material and are more likely to cause clinical effects.
  • Results often require more than one technology to define breakpoints, copy number, and family implications.

Table of Contents

The Main Classes of Structural Variation

Structural variant is an umbrella term for genomic changes that involve a segment of DNA rather than a single nucleotide. Definitions vary by field, but many laboratories use a lower size threshold of about 50 bases. Events can extend from dozens of bases to entire chromosome arms.

Deletions and duplications

A deletion removes a segment of DNA. A duplication adds an extra copy. These are copy-number variants because they change how many copies of the region are present. Their effect depends on size, gene content, dosage sensitivity, inheritance, and whether a critical gene is interrupted at the breakpoint.

A small deletion within one gene may remove an exon and alter the protein reading frame. A large deletion can affect many genes and produce a recognizable syndrome. A duplication may increase gene dosage or insert an extra copy into a location where it disrupts another gene. Copy number alone does not reveal the orientation or insertion site of duplicated material.

Inversions

An inversion occurs when a chromosome segment breaks in two places, rotates 180 degrees, and reinserts. A paracentric inversion lies within one chromosome arm and does not include the centromere. A pericentric inversion spans the centromere.

An inversion may be balanced, meaning no obvious DNA is lost or gained. Even so, a breakpoint can cut through a gene or alter long-range regulation. During egg or sperm formation, a person carrying an inversion may produce gametes with duplicated or deleted segments, depending on inversion size and location.

Translocations

A translocation moves DNA from one chromosome location to another. In a reciprocal translocation, segments from two chromosomes exchange places. A Robertsonian translocation joins the long arms of two acrocentric chromosomes, often with loss of their short-arm material.

A balanced translocation carrier can be healthy if the breakpoints do not disrupt important genes and total dosage remains effectively unchanged. Reproductive risk may still be increased because chromosomes can segregate unevenly during meiosis, producing embryos with extra or missing segments.

In cancer, translocations can create fusion genes or place a growth-promoting gene beside an active regulatory element. These acquired, somatic rearrangements may define a diagnosis or identify a treatment target. Their interpretation is different from that of a constitutional translocation present from birth.

Insertions

An insertion occurs when a DNA segment moves into another position. It may be copied or cut from the original site, and it may be inserted in either orientation. Conventional cytogenetic notation can underestimate complexity because what appears to be a simple insertion may include hidden deletions, inversions, or multiple breakpoints.

Complex rearrangements

Complex structural variants involve several breakpoints or multiple event types. A chromosome can contain a deletion, inversion, and translocation in the same region. Catastrophic processes such as chromothripsis can shatter and reassemble DNA in a highly rearranged pattern. Combining technologies is often necessary to reconstruct the final structure.

Mobile elements and other events

Mobile element insertions add repetitive sequences such as Alu or LINE-1 elements. Other structural changes include tandem repeat expansions, gene conversions, ring chromosomes, isochromosomes, and marker chromosomes. These may require specialized analysis and are not always included in a general structural variant test.

The biological effect is determined not only by size. A small breakpoint that disrupts a dosage-sensitive gene can be more important than a large inherited change in a region tolerant of variation. Precise breakpoint mapping can therefore change interpretation substantially.

Why Balanced Rearrangements Can Matter

“Balanced” means that testing does not show a net gain or loss of genomic material at the resolution of the method used. It does not guarantee that the rearrangement is harmless or perfectly balanced at the base-pair level.

A balanced inversion or translocation can cause disease through several mechanisms:

  • Gene disruption: A breakpoint cuts through a coding sequence, preventing normal protein production.
  • Regulatory disruption: A gene is separated from an enhancer or placed near an inappropriate regulatory element.
  • Fusion formation: Parts of two genes join and produce an abnormal transcript or protein.
  • Position effect: Moving a gene into a different chromatin environment changes its activity.
  • Cryptic imbalance: Small deletions or duplications near the breakpoint are below the resolution of a karyotype.
  • Complexity: Additional inversions or insertions are present but not visible on the initial test.

A person with developmental delay, congenital differences, epilepsy, or another unexplained condition and an apparently balanced de novo rearrangement may benefit from higher-resolution breakpoint analysis. The rearrangement is more suspicious when it arose de novo rather than being inherited from an unaffected parent, although inheritance does not prove benignity because penetrance can vary.

Balanced carriers also face reproductive considerations. During meiosis, paired chromosomes must align despite their altered structure. Several segregation patterns are possible. Some produce balanced or normal gametes; others produce partial trisomy and partial monosomy. The chance of miscarriage or an affected pregnancy depends on the chromosomes, breakpoint positions, size of exchanged segments, sex of the carrier, and family history. A generic percentage should not be assigned without rearrangement-specific counseling.

Robertsonian translocations have distinctive risks. A carrier may have 45 chromosomes but no significant loss of essential genes. Depending on the chromosomes involved, pregnancies can be at increased risk for trisomy 21, trisomy 13, uniparental disomy, miscarriage, or infertility. Homologous Robertsonian translocations create particularly high reproductive risk.

An inversion can also be clinically silent in the carrier yet affect reproduction. Crossing-over within an inversion loop can produce chromosomes with duplications, deletions, or abnormal structures. Some common inversion polymorphisms are benign and do not create substantial reproductive concern; others require individualized assessment.

In cancer, “balanced” is not reassuring. A reciprocal exchange that retains most DNA can activate an oncogene or create a potent fusion. Examples include recurrent translocations in leukemias, lymphomas, and sarcomas. Tumor reports focus on diagnosis, prognosis, and therapy rather than inherited reproductive risk, although some findings can raise suspicion of a germline predisposition.

Which Tests Detect Which Changes

Structural variant testing is a strategy rather than one assay. Each technology observes a different feature of the genome.

Karyotype

A karyotype examines stained chromosomes under a microscope. It can detect aneuploidy and relatively large translocations, inversions, insertions, deletions, duplications, rings, and marker chromosomes. Because the whole chromosome complement is visible, it is valuable for balanced rearrangements and mosaic cell lines.

Resolution is limited. Changes smaller than several million bases may be invisible, and two rearrangements with similar banding patterns can be difficult to distinguish. Cell culture is often required, so turnaround time can be longer and some tissues may not grow successfully.

Fluorescence in situ hybridization

FISH uses fluorescent probes that bind selected chromosome regions. It can confirm a suspected translocation, identify a fusion or break-apart pattern, determine the location of duplicated material, and assess many individual cells for mosaicism. It is targeted: a normal FISH result applies only to the probes used and does not survey the entire genome.

Chromosomal microarray

Microarray measures DNA copy number across the genome and, on SNP arrays, can also identify long regions of homozygosity. It is effective for deletions and duplications that are too small for a karyotype. It generally does not detect truly balanced inversions or reciprocal translocations because no copy-number change occurs. It also may not determine where an extra copy is inserted or its orientation.

Short-read genome sequencing

Genome sequencing analyzes paired reads, split reads, and read depth to detect structural variants. It can map breakpoints more precisely than cytogenetics and may identify small copy-number changes, inversions, translocations, and complex events in one assay. Performance is reduced in repetitive regions, centromeres, segmental duplications, and other sequences where short reads cannot be placed uniquely.

A clinical whole-genome sequencing method must explicitly validate structural variant detection. A laboratory that offers WGS for small variants may not analyze or report every inversion and translocation.

Long-read sequencing

Long reads can span repetitive regions and entire breakpoints, helping resolve complex structures, phase variants, and identify inserted sequence. Clinical availability is growing, but DNA quality, cost, analytic standards, and validation vary. Some events remain difficult even with long reads.

Optical genome mapping

Optical genome mapping labels sequence motifs along ultra-long DNA molecules and compares their pattern with a reference. It can detect large insertions, deletions, inversions, translocations, and complex rearrangements at higher resolution than a karyotype. It does not directly read every base and may require another method to define nucleotide-level breakpoints or small sequence variants.

High-molecular-weight DNA is necessary, so specimen handling differs from routine extraction. OGM is increasingly used in constitutional and cancer cytogenomics, but reporting scope and professional standards continue to evolve.

RNA-based fusion testing

When a rearrangement creates an expressed fusion, RNA sequencing or reverse-transcription PCR can detect the transcript. This can establish functional relevance and identify fusions whose DNA breakpoints lie in large introns. RNA testing cannot find a balanced rearrangement that produces no transcript or is not expressed in the sampled tissue.

Selecting the method begins with the suspected event. Recurrent miscarriage with a possible balanced parental translocation calls for a different first test than a tumor with a suspected kinase fusion or a child with a microdeletion syndrome.

Clinical Reasons for Structural Variant Testing

Constitutional structural variant testing may be ordered for congenital anomalies, developmental delay, intellectual disability, autism, epilepsy, short stature, differences of sex development, unexplained organ disease, or a family history of a chromosome rearrangement. Microarray is commonly used when copy-number imbalance is suspected, while karyotype remains important for large or balanced events.

Infertility and recurrent pregnancy loss

Balanced translocations and inversions can reduce fertility or increase miscarriage risk. A karyotype of both partners may be ordered after recurrent pregnancy loss, severe male-factor infertility, or a pregnancy with an unbalanced chromosome finding. If the karyotype appears normal but family evidence strongly suggests a cryptic rearrangement, genome sequencing or OGM may reveal smaller breakpoints.

Finding a parental balanced rearrangement can explain repeated losses and guide reproductive choices. It does not mean every pregnancy will be affected. Options can include natural conception with prenatal diagnostic testing, preimplantation genetic testing for structural rearrangements, donor gametes, adoption, or no further testing.

Prenatal diagnosis

A fetal structural variant may be detected after an abnormal ultrasound, positive screening test, or known parental rearrangement. Chorionic villus sampling or amniocentesis provides diagnostic material. Microarray identifies copy-number imbalances, and karyotype or FISH can define chromosome structure. Genome-based methods may be considered when conventional results do not explain the phenotype.

Placental mosaicism, maternal cell contamination, and uncertain findings complicate prenatal interpretation. Parental testing often helps determine inheritance and recurrence risk.

Cancer diagnosis and management

Acquired structural variants are central to many hematologic malignancies and solid tumors. A rearrangement may establish a specific diagnosis, define a risk group, predict response to targeted therapy, or provide a marker for monitoring residual disease. Karyotype, FISH, DNA sequencing, and RNA sequencing are frequently complementary.

Tumor heterogeneity and low malignant-cell fraction affect sensitivity. A negative blood or marrow result after treatment can reflect response, but its meaning depends on assay sensitivity and whether the original abnormality is suitable for monitoring.

Clarifying an existing finding

A test may be ordered not to discover a new variant but to resolve one already seen. Microarray may show a duplication without revealing its orientation. Karyotype may show a translocation without defining genes at the breakpoints. Genome sequencing or OGM can refine the structure and change classification or reproductive counseling.

How Structural Variant Results Are Described

Structural variant reports can be difficult to read because they use chromosome coordinates, cytogenetic bands, orientation, copy number, and specialized nomenclature. The report should also provide a plain-language interpretation.

A karyotype result may state the total chromosome number, sex chromosome complement, and rearrangement. For example, notation can indicate a reciprocal translocation between two chromosome bands. “De novo” means the event was not detected in tested parents; “mat” or “pat” may indicate maternal or paternal inheritance.

A sequencing or mapping report may list:

  • genome reference build;
  • chromosome and precise or approximate breakpoints;
  • structural variant type;
  • size;
  • genes disrupted or repositioned;
  • copy-number state;
  • orientation of the segment;
  • supporting read or molecule evidence;
  • mosaic fraction when validated;
  • clinical classification.

A translocation can be reciprocal or nonreciprocal. An inversion can be described by the two breakpoints and whether it is paracentric or pericentric. A complex finding may require a diagram because a linear notation cannot easily communicate the reconstructed chromosomes.

“Balanced” should be interpreted at the resolution of the test. A karyotype-balanced event may contain small losses or gains discovered by microarray or sequencing. The report may therefore use “apparently balanced” until higher-resolution analysis is complete.

In tumor testing, a report may name a fusion gene rather than the chromosome event. The order of gene names can reflect transcript orientation. The report should state whether the fusion was detected at DNA, RNA, or protein level and whether it is known to be actionable in that tumor type.

Mosaic structural variants are present in only a proportion of cells. Karyotype reports may state how many metaphase cells carried the event. Array and sequencing methods estimate mosaic proportion from signal intensity or allele balance. Different tissues can contain different levels, so a blood estimate may not represent another organ.

Classification and Family Risk

Constitutional deletions and duplications are commonly classified as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. Balanced and complex rearrangements require additional reasoning because copy-number frameworks alone do not capture breakpoint disruption and positional effects.

Evidence considered includes:

  • whether the event is de novo or inherited;
  • genes interrupted at breakpoints;
  • dosage sensitivity of deleted or duplicated genes;
  • overlap with known syndromes and population variation;
  • phenotype match;
  • size and genomic content;
  • published cases and functional evidence;
  • segregation with disease in the family;
  • whether RNA studies show a fusion or altered expression.

A pathogenic unbalanced result usually explains or strongly contributes to the phenotype. A variant of uncertain significance means the evidence is insufficient and should not be treated as a confirmed cause. Inheriting a structural variant from a healthy parent can reduce concern but does not always settle the issue because penetrance, mosaicism, and subtle features may differ.

For balanced rearrangements, parental testing serves two purposes. It helps assess causality in the patient and defines reproductive risk in the family. A de novo breakpoint through a known disease gene is more compelling than an inherited rearrangement that has been present in several healthy relatives, although each case requires review.

Once a familial rearrangement is established, relatives should receive targeted testing appropriate to that structure. A simple SNP or single-site sequence test may not detect it. Karyotype, FISH, breakpoint PCR, or another validated method may be needed.

Reproductive counseling should distinguish the carrier’s own health from pregnancy risk. A healthy balanced carrier can still have embryos with unbalanced chromosomes. Risk estimates are individualized and may be based on empirical data, rearrangement structure, carrier sex, and prior pregnancy outcomes.

Limitations, Confirmation, and Next Steps

A negative structural variant test means no reportable event was found within that method’s validated range. It does not exclude all rearrangements. Karyotype misses cryptic events; microarray misses balanced changes; short-read sequencing struggles in repetitive DNA; OGM may miss small variants and does not provide complete base sequence; RNA analysis depends on expression.

Other limitations include insufficient DNA quality, low-level mosaicism, tumor purity, cell-culture bias, incomplete breakpoint resolution, and uncertain gene-disease knowledge. Structural variant callers can disagree, particularly for inversions and insertions. Laboratories often confirm clinically important events with an independent method.

Confirmation is chosen according to the question:

  • FISH can verify location or fusion patterns in many cells.
  • PCR and Sanger sequencing can confirm a precisely predicted breakpoint.
  • Microarray can measure associated gain or loss.
  • Karyotype can show whole-chromosome context.
  • RNA testing can demonstrate an expressed fusion or splice effect.
  • Long-read sequencing can resolve complex or repetitive breakpoints.

After a positive constitutional result, the next steps may include parental studies, genetic counseling, condition-specific care, and testing at-risk relatives. For a child with a de novo complex rearrangement, detailed phenotyping and breakpoint analysis may reveal which disrupted gene explains each feature.

After a balanced parental finding in an infertility evaluation, a reproductive genetics consultation can review miscarriage risk and testing options. Prenatal screening alone may not reliably identify every unbalanced product; diagnostic testing is usually required for a definitive fetal chromosome result.

After a tumor structural variant, oncology and pathology teams should verify whether it is diagnostic, prognostic, or predictive in that cancer. Treatment decisions depend on current evidence, tumor context, prior therapy, and regulatory access, not solely on the presence of a fusion name.

After a negative result with persistent suspicion, choose a complementary platform rather than assuming the genome is structurally normal. Reviewing the raw finding, specimen, and original hypothesis with a clinical geneticist, cytogeneticist, or molecular pathologist can determine whether higher-resolution or tissue-specific testing is justified.

Structural variant interpretation often evolves as breakpoints become more precise and gene regulation is better understood. Keeping the complete report and any chromosome diagrams allows future clinicians to request reinterpretation without repeating the entire diagnostic process.

References

Disclaimer

This article provides general information and does not replace genetic, reproductive, oncology, or prenatal counseling. Structural variant tests differ substantially in resolution, specimen requirements, and detectable event types. Results should be interpreted by qualified professionals using the complete report, family information, and current clinical guidance.

RELATED ARTICLESMORE FROM AUTHOR